Table I.
Correlation between TMSB10 and clinicopathological characteristics of patients with bladder cancer.
| Expression of TMSB10 | ||||
|---|---|---|---|---|
| Clinicopathological characteristics | n | Low, n (%) | High, n (%) | P-value (χ2 test)a |
| Age (years) | ||||
| <65 | 52 | 21 (40.4) | 31 (59.6) | 0.191 |
| ≥65 | 49 | 25 (51.0) | 24 (49.0) | |
| Gender | ||||
| Male | 58 | 28 (48.3) | 30 (51.7) | 0.331 |
| Female | 43 | 18 (41.9) | 25 (58.1) | |
| Histological grade | ||||
| GI | 68 | 31 (45.6) | 37 (54.4) | 0.580 |
| GII–III | 33 | 15 (45.5) | 18 (54.5) | |
| T stage | ||||
| Ta-T1 | 48 | 27 (56.3) | 21 (43.8) | 0.032 |
| T2-T4 | 53 | 19 (35.8) | 34 (64.2) | |
| Distant metastasis | ||||
| Absent | 90 | 41 (45.6) | 49 (54.4) | 0.625 |
| Present | 11 | 5 (45.5) | 6 (54.5) | |
| Multiplicity | ||||
| Single | 71 | 33 (46.5) | 38 (53.5) | 0.473 |
| Multiple | 30 | 13 (43.3) | 17 (56.7) | |
a
Values in bold are considered statistically significant. TMSB0, thymosin β10.